PureTech Health plc (LON:PRTC)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 296.00M +5.6% |
| Revenue (ttm) | 3.46M -3.5% |
| Net Income | -81.54M |
| EPS | -0.34 |
| Shares Out | 243.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 837,631 |
| Open | 126.00 |
| Previous Close | 126.00 |
| Day's Range | 119.80 - 126.00 |
| 52-Week Range | 104.70 - 143.60 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 331.23 (+172.39%) |
| Earnings Date | Sep 22, 2026 |
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformati... [Read more]
Analyst Summary
According to 4 analysts, the average rating for PRTC stock is "Strong Buy." The 12-month stock price target is 331p, which is an increase of 172.39% from the latest price.
News
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress.
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of IPF.
PureTech entity Celea raises $180 million to move lung disease drug into late stage trial
Celea Therapeutics, linked to PureTech Health , on Thursday completed a $180 million financing round for a late-stage trial of its lung disease drug, deupirfenidone, in patients with idiopathic pulm...
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to IPF.
PureTech Health: Results of Annual General Meeting
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting.
PureTech Health Earnings Call Transcript: H2 2025
Refined strategy emphasizes operational efficiency, early spin-outs, and disciplined capital allocation. Cash runway extends through 2028, with major progress in Celea and Gallop clinical programs and a focus on returning capital to shareholders after significant inflows.
PureTech Health Annual report: H2 2025
PureTech Health has published its H2 2025 annual report on April 29, 2026.
PureTech Health Annual report: H2 2025
PureTech Health has published its H2 2025 annual report on April 29, 2026.
PureTech Health Annual report: H2 2025
PureTech Health has published its H2 2025 annual report on April 29, 2026.
PureTech Health Transcript: Leerink Global Healthcare Conference 2026
The conference highlighted a robust hub-and-spoke model driving innovation and value through spin-outs, with strong clinical progress in IPF and oncology. Deupirfenidone is poised for a pivotal phase 3 trial, and the company remains self-funded with significant future milestones expected.
PureTech Health Transcript: 44th Annual J.P. Morgan Healthcare Conference
A diversified hub-and-spoke model drives innovation and financial returns by spinning out de-risked drug programs, with a strong track record of clinical and commercial success. Key assets Celea and Gallop are advancing to pivotal trials, while the company remains self-funded and focused on efficient capital allocation.